Phaseline

Companies › Triveni Bio

Triveni Bio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Immunology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRIV-509–Phase 2Atopic DermatitisJun 2027
TRIV-573–Phase 2Atopic DermatitisAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07167758TRIV-509Phase 2Atopic DermatitisImmunologyJun 2027
NCT07782333TRIV-573Phase 2Atopic DermatitisImmunologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

MRM Health Citryll Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.